Member Info for JimiHendrix

Https://youtu.be/upRV54z_AzU?si=m_5njPQMp2CB76GK

Interesting how the price has moved the past few sessions on very little buying. Background buyer perhaps?

“won't be able to stop Gino and Russ coming to share holders asking for approval if it requires a vote and they have a decent offer, especially if the offer is open to all pis”

Well actually I don’t think there’s any legal reason stopping him from voting NO again, it was David alone that swayed the vote. Maybe there will be terms in the deal that he has to do what’s best for shareholders (as he would do if on the board).

My expectation is the next big thing will be evidence generation completion and submission early next year. In the meantime we may hear about further adoption in Scotland and/or further uptake in England for CYP2C19.

April 2026 – New NHS MedTech Funding Mandate goes live... This is the moment for the RNR1 test imo.

Under the new MTT / MTI reforms:

Technologies that save money and improve outcomes, with strong evidence – Receive central NHS budget.

RNR1 is an ideal candidate because:

Adverse drug reactions cost huge sums.

Hearing loss prevention is massively cost-saving.

Neonatal ICUs co-developed the original studies

Genetic safety tests are a priority area

If selected, this becomes the single most important commercial inflection since the company was founded.

NICE evidence generation is expected to wrap early 2026. Once submitted, NICE can then move toward updating guidance. The NHS med-tech funding reforms coming in April 2026 massively favour national commissioning of cost-saving genetic safety tests. This is the test most likely to “go big” fastest.

April 2026 National MedTech Mandate changes

This is huge. The new MTT/MTI system (replacing MTI1–3) means:

Low-cost diagnostics with strong health-economic evidence get centralised funding from April 2026.

Hospitals don’t need to find their own local cash.

RNR1’s £10–£30k per baby hearing-loss avoidance savings make it a poster child.

Impact:

Genedrive is positioning RNR1 to be one of the first wave nationally bought-in technologies.

*tranche

Tranche 1 = a short-term financing buffer

Tranche 2 = not available until late Feb 2026

Board + Nugent both want to ensure the company survives long enough to reach this six-month catalyst cluster.

If revenues and tax rebate land in time, they may never need Tranche 2.

This is classic strategic runway planning: Buy time until value arrives.

H1 2026 is the convergence of:

• RNR1 evidence completion

• National commissioning reforms (April 2026)

• Stroke test rollout (implementation guide expected well before then)

• Saudi agreement follow-through

• FDA pathway

• R&D tax refund

• And broadened revenue opportunities

There's also the approx £800k cash boost from R&D tax rebate that will likely land March 2026. So now including David's loan they will have breathing room into summer, not including expected increased revenue from NHS adoption and more.

I expect they will probably not need to draw down the second trench, it is likely a backup option incase the tax rebate is delayed.

Fantastic news, thanks David! The share price should push up from here now.

If the loan is confirmed I wouldn’t be surprised to see 1.5p. Higher if it’s sales or adoption related news.

Well you posted an older negative RNS, that was announced before the more recent positive one about the potential loan.

Eureka, you’ve become a deramper lol. Conveniently missed the last RNS about DN…

“ Since the Company's general meeting on 15 October 2025 the Company has continued to engage constructively with David Nugent around financing options for the Company and to this end he has recently indicated a willingness to make a direct cash injection into the Company by way of a loan of up to £1 million on terms to be agreed between the parties. Whilst there can be no certainty that this additional funding will be received the Company welcomes this indication of potential additional financial support from David Nugent and further announcements will be made in due course. ”

Haha, basically just to say assays are pending.

No real new news here.

Mcap is usually around 10 times earnings, so if we get £20m per year we may see 20p share price.

On balance the rules-based NHS medtech pathway (expected to go live in April 2026) is more likely to benefit MT-RNR1 first. The patient-safety case is unusually clear: a rapid test prevents severe, irreversible harm (profound hearing loss) that can occur after a single aminoglycoside dose, and there’s no practical lab alternative that delivers a genotype before first-line antibiotics in NICU. That ticks classic mandate boxes (clear harm avoided, net cost savings over a lifetime, simple workflow, concentrated adoption in a finite set of neonatal units). Put bluntly, it’s the kind of technology that’s easy for a national body to back without getting lost in pathway politics.

NICE set the evidence-generation period at 3 years for MT-RNR1 under its Early Value Assessment. Because the EVA guidance was published on 30 March 2023, that points to an expected finish around March 2026, after which NICE reviews the submitted data for a decision on routine adoption.

...

Could be rather good timing! Perhaps RNR1 national commissioning is next, thanks to the upcoming new funding pathway?

That’s the way it’s done currently but that’s expected to change in April.

Eureka, I think you sold out before you posted yesterday lol!

It’s been clear for a while that lab testing can’t provide the speed needed, reliably and consistently across the UK. NHS have co developed the POC test to fill in the gaps and for HASUs, who need really quick results.

Bootnik, I think it’s obvious that it WILL be rolled out nationally…

If the rules-based NHS medtech pathway with mandated funding goes live in April 2026 as signposted, it’s a clear positive for Genedrive’s CYP2C19 point-of-care stroke test. Today, even with supportive evidence, adoption in the NHS tends to crawl because every trust/ICB has to build its own business case and find local budget. A rules-based, nationally funded route changes that dynamic: it can set central money flows, standardise procurement, and hard-wire uptake expectations. In practical terms, it removes the biggest friction to scale (piecemeal funding) and turns a trust-by-trust sell into a nationally enabled roll-out.

Here you go this explains it…

If the rules-based NHS medtech pathway with mandated funding goes live in April 2026 as signposted, it’s a clear positive for Genedrive’s CYP2C19 point-of-care stroke test. Today, even with supportive evidence, adoption in the NHS tends to crawl because every trust/ICB has to build its own business case and find local budget. A rules-based, nationally funded route changes that dynamic: it can set central money flows, standardise procurement, and hard-wire uptake expectations. In practical terms, it removes the biggest friction to scale (piecemeal funding) and turns a trust-by-trust sell into a nationally enabled roll-out.

CYP2C19 benefits specifically because stroke/TIA treatment is time-critical. If the pathway or associated toolkits set turnaround targets that labs struggle to meet consistently across 24/7 pathways, trusts will need bedside POC to comply. That naturally favours Genedrive’s proposition (rapid genotype before antiplatelet decisions in HASUs/EDs). Add in the NHSE pilot learnings and any implementation guidance on workflow, and you have both the clinical rationale and a funding mechanism aligned—likely pulling adoption forward and widening the addressable share versus a slow, organic site-by-site approach.

It’s changing in April, if Genedrive’s PIC is added to the list it’ll be commissioned through a new funding pathway. It’s mentioned in the trading update.